TY - JOUR
T1 - Natamycin in the treatment of fungal keratitis
T2 - A systematic review and Meta-analysis
AU - Qiu, Sheng
AU - Zhao, Gui Qiu
AU - Lin, Jing
AU - Wang, Xue
AU - Hu, Li Ting
AU - Du, Zhao Dong
AU - Wang, Qian
AU - Zhu, Cheng Cheng
N1 - Publisher Copyright:
© 2015, International Journal of Ophthalmology (c/o Editorial Office). All rights reserved.
PY - 2015/6/18
Y1 - 2015/6/18
N2 - AIM: To review published clinical studies examining the effect of natamycin in the treatment of fungal keratitis. • METHODS:We selected the publications in CENTRAL, MEDLINE, EMBASE, CNKI, and CBM. This study systematically reviewed published randomized controlled trials (RCTs) that compared natamycin to other antifungal agents, and conducted feasible Meta-analysis of efficacy results using Revman 5.2 software. • RESULTS: We included seven trials which were mainly carried out in developing countries of Asia, with five trials conducted in India, one each in China and Bangladesh. A total of 804 participants were randomized to following comparisons:2% econazole versus 5% natamycin showed little difference in the effects of treatment of fungal keratitis [RR=0.99, 95% confidence interval (CI), 0.8 to 1.21]; chlorhexidine gluconate versus 5% natamycin indicated that the results on healing of the ulcer at 21d was less conclusive (RR=0.77, 95% CI, 0.55 to 1.08; I2=0%); 1% voriconazole versus 5% natamycin suggested that natamycin treatment appeared to be significantly better outcomes than voriconazole (regression coefficient =-0.18 logMAR; 95% CI, -0.30 to -0.05; P=0.006), especially in Fusarium cases (regression coefficient=-0.41 logMAR; 95% CI, -0.61 to -0.20; P<0.001); natamycin versus fluconazole showed a significant difference in cure rate (χ2 =5.048, P<0.05) and natamycin group was more effective than fluconazole in average period of therapy (t=7.94, P<0.01). • CONCLUSION: Natamycin was a preferable choice in the treatment of fungal keratitis, especially in the early period of Fusarium cases.
AB - AIM: To review published clinical studies examining the effect of natamycin in the treatment of fungal keratitis. • METHODS:We selected the publications in CENTRAL, MEDLINE, EMBASE, CNKI, and CBM. This study systematically reviewed published randomized controlled trials (RCTs) that compared natamycin to other antifungal agents, and conducted feasible Meta-analysis of efficacy results using Revman 5.2 software. • RESULTS: We included seven trials which were mainly carried out in developing countries of Asia, with five trials conducted in India, one each in China and Bangladesh. A total of 804 participants were randomized to following comparisons:2% econazole versus 5% natamycin showed little difference in the effects of treatment of fungal keratitis [RR=0.99, 95% confidence interval (CI), 0.8 to 1.21]; chlorhexidine gluconate versus 5% natamycin indicated that the results on healing of the ulcer at 21d was less conclusive (RR=0.77, 95% CI, 0.55 to 1.08; I2=0%); 1% voriconazole versus 5% natamycin suggested that natamycin treatment appeared to be significantly better outcomes than voriconazole (regression coefficient =-0.18 logMAR; 95% CI, -0.30 to -0.05; P=0.006), especially in Fusarium cases (regression coefficient=-0.41 logMAR; 95% CI, -0.61 to -0.20; P<0.001); natamycin versus fluconazole showed a significant difference in cure rate (χ2 =5.048, P<0.05) and natamycin group was more effective than fluconazole in average period of therapy (t=7.94, P<0.01). • CONCLUSION: Natamycin was a preferable choice in the treatment of fungal keratitis, especially in the early period of Fusarium cases.
KW - Eye infection
KW - Fungal
KW - Meta-analysis
KW - Natamycin
UR - http://www.scopus.com/inward/record.url?scp=84938820310&partnerID=8YFLogxK
U2 - 10.3980/j.issn.2222-3959.2015.03.29
DO - 10.3980/j.issn.2222-3959.2015.03.29
M3 - Article
AN - SCOPUS:84938820310
SN - 2222-3959
VL - 8
SP - 597
EP - 602
JO - International Journal of Ophthalmology
JF - International Journal of Ophthalmology
IS - 3
ER -